Life Sciences Archive » June, 2020

Life Sciences - June, 2020

416 articles

• 3 Developments As HHS Officials Paint Dark Pandemic Picture
• Legal Teams Vie To Lead COVID Test Supply Stock Drop Suit
• Medical Parts Co. Says $74M Fight Doesn't Belong In Ga.
• Ex-Indivior CEO Cops To Misdemeanor In Opioid Case
• DOJ Charges Glenmark With Generic Drug Price-Fixing
• Biogen Gets Temporary Halt On Unapproved Mylan MS Drug
• Justices Told Congress Must Craft PTAB Constitutional Fix
• Procopio Boosts IP Practice In Calif. With 7 Arent Fox Attys
• SEC Fines Ex-Biotech CEO For Fertility Drug Misstatements
• Genomic Health Investor Calls Exact Sciences Merger Unfair
• Colorado Gov. Signs Cannabis Social Equity Bill Into Law
• Imerys Ch. 11 Sale Process OK'd Despite Insurer Concerns
• Virus Delays Second Round Of Illinois Marijuana Licenses
• Coronavirus Regulations: A State-By-State Week In Review
• What You Say In Online Mediation May Be Discoverable
• Why FDA's Proposed Food Standard Principles Are Important
• Key Defense Approaches To 'Other Similar Incident' Evidence
• Amputee's Widow Aims To Keep Bayer, Merck On The Hook
• BlackRock Joins Goldfinch Bio's $100M Series B Round
• Trade Groups Face Antitrust Questions In Pandemic Response
• IP Risks To Consider When Joining 'Open COVID Pledge'
• UK Watchdog Skeptical Of Stryker's $4B Wright Medical Deal
• 9th Circ. Won't Revive PetIQ Merger Challenge
• Pfizer Calls For Fees On US Merck Pneumonia Vaccine At Trial
• Pharmacies Urge 6th Circ. To Boot Opioid MDL Judge
• Bayer, Beiersdorf Can't Ditch Or Move Coppertone Claims
• Advocates Unimpressed With Iowa Low-THC Program Tweaks
• AmerisourceBergen CEO Must Testify In Opioid Bellwether
• Justices Told PTAB Appointments Are Not Unconstitutional
• Bayer, GE Must Face Suit Over Woman's Chemical Sickness
• Fortress Drops Ex-Theranos IP Suit To Let Test Co. Fight Virus
• Endo Investors Seek Cert. After Losing Price-Fixing Claims
• House Passes Dems' ACA Booster Bill Despite Veto Threat
• Sens. Add Marijuana Research Expansion To Defense Bill
• Labaton Sucharow To Lead Abiomed Stock-Drop Class Action
• Calif. Delays Pot Licensing Fees Amid Pandemic
• Top 6 Patent Rulings Of 2020: A Midyear Report
• Covington, Freshfields-Led Biotech Co. Nabs $251M Financing
• Mylan Hit With Stock-Drop Suit Over Test Manipulation
• Nursery Tells 11th Circ. Pot License Constitutionally Protected
• Treat Hemp Like Any Other Industry, FinCEN Urges
• FDA Ducks Suit Challenging Stimulant Crackdown
• 9th Circ. Told To Dig Into 'Tribunal' Meaning In Discovery Fight
• Mass. Court Deadline Tolling Will Cause Problems For Years
• 10 Tips For A Successful Remote Arbitration Hearing
• J&J Can't Beat $186M Punitive Award In Talc Asbestos Case
• Pfizer Says HHS Is Blocking Patient Access To Heart Drugs
• J&J Put In A Corner By Court That Slashed $4.7B Talc Verdict
• Dispensary Says Md. Pot Board Discrimination Case Tenable
• 3rd Circ. Urged To Revive Pelvic Mesh Atty Fees Suit
• COVID-19 IP Catch-Up: Mask Sales & Remote Source Codes
• Fresenius Takes Fiery Aim At Akorn's Ch. 11 Plan Disclosures
• Inovio Can't Force Supplier To Share COVID-19 Vaccine Tech
• 5 Tech And Life Sciences Cos. Raise Nearly $1B Total In IPOs
• High Court's SEC Enforcement Ruling Has Tax Consequences
• Surescripts Says Pharmacies' Antitrust Claims Too Indirect
• Talc Maker Can't Interview Ex-Jurors After Virus Mistrial
• Latham-Led Pesticide Group Lands $45M Funding Round
• 7th Circ. Won't Revive Merck Employee Bias Suit
• Insys Founder Says 4th Circ. Ruling Aids New Trial Bid
• 5th Circ. Snuffs Challenge To FDA Regulation Of E-Cigs
• Celgene Fights Investors' Class Cert. Bid In Stock-Drop Suit
• To Achieve Diversity, Law Firms Must Reinvent Hiring Process
• Taxation With Representation: Simpson, Cadwalader, Latham
• A New Antitrust Approach After Humira 'Patent Thicket' Ruling
• UK Litigation Roundup: Here's What You Missed In London
• 'Compound King' Gets 10 Years For $22M Health Care Fraud
• Cities May Seek Statewide UCL Relief, Calif. Justices Say
• Chief SDNY Judge Says Drug Cos. Ready For Remote IP Trial
• Robbins Geller Will Lead Investor Suit Against Mallinckrodt
• 5th Circ. Won't Revive Suit Against Allergy Advocacy Group
• AbbVie, FTC Tussle Over High Court's View On Disgorgement
• GNC Can Tap Into Ch. 11 Funds Despite Creditor Opposition
• Cannabis Cos. Settle Supply Agreement Dispute For $21M
• Investors Fight CBD Co.'s Bid To Ax Suit Over Clinical Trial
• Cybersecurity Steps For Law Firms Amid Heightened Risks
• 4 Tips For Defending Consolidated Cases
• Army Wants To Reconsider Disputed Medicine Dispenser Deal
• Hong Kong Cancer Drug Co. Snags $100M Equity Investment
• Bayer Ducks Suit Over Birth Control Device Defect Claims
• Congress Could Still Pass Cannabis Legislation In 2020
• Consumer Device Data May Pose Problems In Med Mal Suits
• Cancer Biotech Lands $110M In Financing, Refiles For IPO
• Novartis Units Pay $346M Over US Bribery Claims
• Bayer Offers $400M To Settle Dicamba Suits With Farmers
• J&J Surgical Rip-Offs Lead To Seizure, FDA Criminal Probe
• Full Fed. Circ. Skips Biogen Fight Over MS Drug Patent
• Acuity Must Defend Pharma Co. In Opioid Liability Suits
• Mich. Pot Industry Expects A Boost From Regulatory Overhaul
• Prevagen Maker Inks Deal To Settle Half-Dozen False Ad Suits
• Ex-Marine Aims To Kill 3M Suit Alleging Massive N95 Scam
• Regeneron Paid Kickbacks To Boost Eye Drug, Feds Say
• State Farm Faces Suit By Chiropractor Over 'Virus Exclusion'
• An Inside Look At DOJ Fight Against COVID-19 Price-Gouging
• The Research Compliance Landscape Is Evolving Quickly
• A Strategy To Address Uncertainty In Life Sciences Contracts
• UK Justices' Regeneron Ruling Puts Hurdle In Biotech IP Race
• Class Cert. Denied In Suit Over Faulty Embryo Storage Tank
• It's Time For Law Firms To Support Work-From-Home Culture
• Republicans Keep Confirming Unqualified Judicial Nominees
• With $10B Deal, Bayer Aims To Put Roundup Battles Behind It
• How Trump Forever Changed Judicial Nominations
• GNC Falls Into Ch. 11 Due To COVID-19 With $1B-Plus Debt
• Top UK Court Invalidates Regeneron's Lab Mice Patents
• Court Trims Challenge To Ill. Cannabis Licensing Scheme
• Top Health Officials Contradict Trump On Pandemic Response
• Bayer Foe Blocked From Serving Docs Via Email Amid Virus
• Agencies Hit With FOIA Suit Over Request For DNA Docs
• Walmart Accused Of Misrepresenting Toddler Formula
• Gilead To Buy 49.9% Stake In Latham-Led Drug Co. For $275M
• Philips Says Chinese Rivals Can't Skirt Ill. Trade Secret Suit
• Obviousness Doomed Narcan Patents After NJ Bench Trial
• Omnicell Says DOD Bid Process Altered To Kill Competition
• Shareholder Suit Over GTx And Oncternal Merger Tossed
• Valeant Tells Full Fed. Circ. Relistor Patent Ruling Is 'Alarming'
• Medical Services Co. Seeks Arbitration In Trade Secret Fight
• Chicago Says Drug Cos. Shouldn't Exit Opioid Bellwether Suit
• High Court Missed Chance To Define SEC Enforcement Limits
• 9th Circ. Won't Revive Cannabis Patient's Eviction Challenge
• Tips For Crafting The Perfect Law Firm Alert
• Coronavirus Regulations: A State-By-State Week In Review
• Pandemic May Push 1st Zofran MDL Bellwether To 2021
• Purdue Gets OK For $6.5M Investment In Overdose Drug
• Mo. Appeals Court Slashes $4.7B Talc Verdict Against J&J
• Purdue Wants Sackler Claims To Stay Blocked By Ch. 11
• Biopharma Patentees Must Navigate Inherent Obviousness
• 7th Circ. Won't Revive 'Perplexing' AbbVie Stock Drop Suit
• Alere Tells PTAB To Reconsider New Record On SAS Remand
• FDA Says To Avoid 9 Potentially Harmful Hand Sanitizers
• Atty, Co. Must Pay Sanctions After Tossed Takeda Unit Suit
• Travelers Drops Suit Claiming Qatar Airways Damaged Cargo
• Cook Medical Wants Fraud Claims Tossed From MDL
• CORRECTED: Monsanto Blocks Calif. Glyphosate Cancer Warning Label
• Mo. Medical Pot Regulators Probe Fraudulent Patient Licenses
• 4 Cos. Join Busy IPO Pipeline With Launches Totaling $598M
• Novartis Seeks To Block Imports Of German-Made Eye Shots
• Judging A Book: Elrod Reviews 'Shortlisted'
• Mandatory State Bars Likely To Remain Intact, For Now
• Genetics Co. Inks $1.4B Deal With Cooley-Led Cancer Tech Biz
• Justices Skip Retroactive IPRs, Doctrine Of Equivalents
• Investor Says Endo Lied About Role In NY Opioid Crisis
• Shareholders Seek Class Cert. In Teva Price-Fixing Suit
• Roundup Atty, Partner Cop To $200M Corporate Extortion Plot
• 4th Circ. Orders New Trial For W.Va. Doctor In Opioid Case
• 4 Life Sciences Companies Price IPOs Totaling $854M
• Cigar Groups Ask Full 4th Circ. To Allow E-Cig Rule Challenge
• FTC Sends Another Round Of COVID-19 Warnings
• COVID-19 IP Catch-Up: Trials Get Delayed, Moved To Video
• If We Used Current Patent-Eligibility Tests On Vintage Patents
• When Is The Hypothetical Negotiation For Patent Damages?
• 11 Keys To Success At Remote Mediation
• Hot Air Balloons Face Pesticide Risk, Calif. Farm Tells EPA
• Diagnostics Co. Sued After COVID-19 Test Revoked By FDA
• Essure Negligence Suit Shouldn't Be In Pa. Court, Bayer Says
• Wright Medical, MicroPort Don't Want Implant Suits In MDL
• Vaccine Co. Must Face Claim It Illegally Refused Job Applicant
• Robbins Geller Will Lead Proposed Inovio Investor Class
• Pharma Co. Must Mediate EpiPen Pricing Claims With Mylan
• Perrigo Inks $195M Sale Of UK Generics Manufacturer
• UK Litigation Roundup: Here's What You Missed In London
• 3 Trends Underlying The Boom In Blank-Check IPOs
• Fed. Circ. Grants Arthrex Remand In Ex Parte Reexam
• Mylan Gets Biogen MS Drug Patent Invalidated In W.Va. Court
• Smart-Pill Maker Plans Ch.11 Sale Of 'Science Fiction'-Like IP
• EPA Lists New Substance As Hazardous Under Clean Air Act
• 3M Settles Another Price-Gouging TM Case Over N95 Masks
• DOJ Wants To Keep Generic-Drug Exec's Case In Pa.
• FDA Opens Useful Dialogue On Orange Book Patent Listings
• Pa. Justices Scrap Ban On Medical Pot For Probationers
• Pandemic Could Bring Student Exodus From Legal Profession
• Walmart Investors Want Docs To Probe Role In Opioid Crisis
• Chinese Co. Charged With Selling Defective Respirator Masks
• Deals Rumor Mill: Bombardier, Thyssenkrupp, CureVac
• Justices Told Suboxone Ruling Lets PTAB 'Do As It Pleases'
• Maine Cannabis Residence Suits Raise Thorny Federal Issues
• Mylan Faces Fight To Bar Generic Sleep Aid As Launch Nears
• Edwards Can't Fully Launch Heart Device Amid Patent Appeal
• Virus Fears Mean Serenity, Ferring Will Have Remote IP Trial
• Shire Wants Jury Trial Over Validity Of Its Genetic Disorder IP
• 3 Patent Changes Can Boost Economic Growth, Profs Say
• Pot Co. Trulieve Seeks Quick Win In Background Check Row
• EPA Defends Its Revised Dicamba Policy After 9th Circ. Order
• Reed Smith Reps Perrigo's $50M Investment In CBD Supplier
• EPA Should Reexamine Fluoridated Water Risks, Judge Says
• Health Hires: Latham, Fox Rothschild, Saul Ewing
• Generic Cos. Ask Fed. Circ. To Deny Amarin's Vascepa Appeal
• Ex-Okla. GC Who Faked Email Threats Gets Suspension
• How To Handle Congressional Queries On COVID-19 Relief
• The Privilege Implications Of Using Online Collaboration Tools
• MDL Decisions Demonstrate The Need For Rule 702 Reform
• Biotech Co. Investors' FDA Convo Suit Survives Dismissal Bid
• J&J Says Imerys Ch. 11 Plan Lacks Info
• Calif. High Court Could Limit DA Enforcement Actions
• Pharmacies Want Out Of Opioid MDL 'Public Nuisance' Suits
• Boehringer Ingelheim Sued For €23M Over Diabetes Drug IP
• USTR Plans To Hold Mexico's Feet To Fire Under Trade Deal
• Lab Software Co. Says Worker's Visa Denial Hurts Virus Fight
• EPA Risk Assessment Director Stands By Fluoridated Water
• J&J CEO Falsely Painted As A Crook At Talc Trial, Court Told
• Worker Says She Was Fired Over Empty Medical Pot Package
• DC Circ. Rejects Trump's 'Far-Flung' Drug Pricing Rule
• Biotech Co. Asks 4th Circ. To Toss $22M Defamation Verdict
• Illumina Wins Bid To Block BGI Genomics' DNA Product Sales
• Royalty Pharma Raises $2.2B In Year's Largest IPO
• Post-Transaction Privilege Lessons From Del. M&A Opinion
• FDA Issues Warnings Over Unapproved Homeopathic Drugs
• Confronting Mental Distress In The Legal Profession
• Coronavirus Regulations: A State-By-State Week In Review
• Eagle Fights FDA's DC Circ. Bid To Undo Orphan Drug Win
• 'Pharma Bro' Shkreli Can't Delay Discovery In Antitrust Suit
• Banks May Need To Update Policies To Fight COVID-19 Fraud
• Native American Tribes Say Juul Targeted Them With Vapes
• How USPTO Examiner Type Affects Patents: Part 2
• Smart-Pill Maker Proteus Hits Ch. 11 After Cash Crunch
• Malaria Meds Don't Cure Virus, May Hinder Gilead Drug: FDA
• High Court Skips Challenge Over Doctrine Of Equivalents
• EPA Experts Say Fluoride Not Shown Toxic At Low Levels
• CBD Co. Execs Hit With Derivative Suit Over Patent Rejection
• USPTO To Speed Up Pandemic-Related TM Applications
• Inovio's '3-Hour' COVID Cure Claims Spark Derivative Suit
• Swedish Pharma Co. Targets US Partner In Arbitration
• Fla. Cannabis Co. Taps BigLaw Vet As Chief Legal Officer
• Centene Settles Hep C Class Suit
• COVID-19 Test Maker Sued Over '100% Accurate' Claim
• Litigation Finance Investments Are Not Risk-Free Loans
• $88M Cut From Requested $157.5M Atty Fee In Namenda Deal
• Minn. Senate Bill Floats Legalizing, Taxing Recreational Pot
• 4 Life Sciences Companies Launch IPOs Totaling $588M
• Pharmacies Can't Avoid Common Discovery In Opioid MDL
• High Court Won't Hear Drug Price-Fixing Discovery Dispute
• How Cos. Can Avoid Patent Venue Pitfalls Of Remote Work
• Ropes Helps Novavax Ink $200M PIPE Deal To Fight COVID-19
• High Court Takes Up Arbitration Carveout Question
• How White Privilege Helped Me Succeed In BigLaw
• EPA Defends Safety Of Fluoridated Drinking Water At Trial
• Cherokee Nation Fights Bid To Nix Opioid Bellwether
• 4 Takeaways As AbbVie Crushes 'Patent Thicket' Litigation
• Teva's $25M Consumer Settlement Gets Green Light
• Texas High Court Limits Forum Clauses To Signatories
• Safeway Escapes Whistleblower's Drug Price Suit
• Social Equity Lags Behind Progress In Pot Industry
• CVS-Only HIV Drugs Deny Meaningful Access, 9th Circ. Told
• Fed. Circ. OKs Medinol Patent Loss Despite Ax Of Laches
• Cannabis Bill Roundup: Colo. Fast-Tracks Social Equity Bill
• Stroock Nabs Greenberg Traurig Litigation Pro For NY Office
• Nature's Way Can't Dodge Revived Ginkgo Class Action
• 11th Circ. Won't Revive Female J&J Worker's Sex Bias Row
• Green Groups Ask 9th Circ. To Force Immediate Herbicide Ban
• Biotech Cos. Flood Public Markets With IPOs Over $900M
• Fed. Court No Place For Pot License Fight, Md. Agency Says
• Travelers Sues Qatar Airways Over $81M Cargo Damage
• $25M Penny Stock Scam Used COVID-19 Ruse, Feds Say
• Catalent Escapes Muslim Worker's Suit Over Prayer Breaks
• Coronavirus Q&A: Ropes & Gray's Tara Fisher
• Novartis Can't Duck Suit Over Cancer Drug Side Effects
• DSM Boosts Animal Gut Health Biz With €980M Erber Deal
• Robbins Geller Sues SEC For OvaScience Probe Docs
• Calif. Appeals Court Affirms Chemical's Listing As Carcinogen
• Coronavirus Q&A: Honigman's Life Sciences IP Leader
• CBD Co. Hits Back At Charlotte's Web In TM Row
• Congress Must Create More Private Rights Of Action
• Keys To A Thriving Biz Development Culture At Your Law Firm
• Davis Polk, Goodwin Steer Pharma Deal Worth Up To $2.1B
• Amazon, EBay Told To Stop Selling Unproven Virus Cleaners
• 1st Circ. Generic-Delay Ruling Isn't Popular With Lower Courts
• Philip Morris Taps Manatt Atty As General Counsel
• Hiscox Must Fund NY Drug Biz's Defense In Opioid Trial
• EPA Scientist Testifies Animal Studies Point To Fluoride Risks
• Cigna Jumps Into Pharmaceutical Generics Price-Fixing Fight
• Insys Manager Who Flipped On Bosses Avoids Prison Time
• 9th Circ. Rules Endologix Stock Suit 'Had No Basis In Logic'
• AGs Pile On Generics Cos. With 3rd Price-Fixing Complaint
• Fla. Pot Licensing Law Not Unconstitutional, Nursery Says
• COVID-19 Vaccine Developers Can Limit Liability From Trials
• Fed. Circ. Patent Rulings May Shift Use Of Motion To Dismiss
• How Video Mediation Can Help Us Serve Clients Better
• Buyer Says Muscle Supplements Contain Carcinogen
• Ex-GC Eyes Early Win Against CBD Co. Over Stocks, Benefits
• Calif. Backs Patent Atty's Whistleblower Suit Against Allergan
• Kessler Topaz Named Lead Counsel In Becton Securities Suit
• Mental Health Efforts Will Support Diversity In Legal Industry
• Feds Charge Biotech Exec, Investor In COVID-19 Test Scam
• Fluoride In Water Is 'Endangering' Children's IQs, Judge Told
• GAO Says Outdated Inventory System Hurt VA Virus Response
• Merck Can't Wipe Out Microspherix's PTAB Win
• Insulin Wholesalers Want Consumers To Get Out Of Their Way
• FTC, Impax Spar At 5th Circ. Over Opana ER Deal
• Foley Hoag Hires Ex-Norton Rose Patent Partner In NY
• Zantac Users Push To Consolidate Calif. Cancer Suits
• PetIQ Merger Fight Faces Skeptical Judge At 9th Circ.
• Coronavirus Regulations: A State-By-State Week In Review
• State Of Enviro Enforcement After Trump's Deregulatory Order
• Feds Tell High Court To Reject Arthrex Appeal On IPR
• UK Clears Elanco's $135M Divestiture For Bayer Deal
• Servier Urges Justices To Play By EU Pay-For-Delay Ruling
• Patent Specification Has Become Vital For Nonabstract Claims
• Medical Packager Says Union Staff Can't Sue In Privacy Fight
• Law Profs Urge Fed. Circ. To Narrow Assignor Estoppel Rule
• Bull Semen Co. Boosts Win Against Rival To $11M In IP Row
• Bayer, Merck Beat Dr. Scholl's Buyer's Leg Amputation Suit
• SEC Cuts Accountant Slack For Self-Reporting Insider Trading
• Judge Says Cert. Unlikely For Parent ADHD Med Buyers
• Texas Hemp Group Asks State To Allow Sale Of Smokables
• Jailed Biotech Inside Trader Gets 5-Year Ban In SEC Case
• Bankruptcy Court Can't Touch Pot Patent, Trustee Says
• General Dynamics Unit Must Face $13M Contract Breach Suit
• EPA Cancels Approval Of Dicamba Pesticide
• 3M Sues Amazon Seller Over Fake N95 Masks
• FTC, States Fight Shkreli Bid To Delay Antitrust Suit Discovery
• AbbVie Beats Antitrust Challenge To Humira 'Patent Thicket'
• New Ruling May Aid Syndicated Loan Market Amid Pandemic
• Supplements Co. Hit With Suit Over Muscle-Building Claims
• Royalty Pharma Leads Life Sci Trio Set To Raise $2.2B In IPOs
• EU Approves Elanco's $7.6B Bayer Animal Biz Buy
• What State Laws On COVID-19 Liability Protection Look Like
• Pandemic Collaborations Pose Risk Of Future Patent Disputes
• COVID-19 Product Liability And The 'Innocent Seller'
• Workers Insist Yale's Wellness Program Not Really 'Voluntary'
• Civility Could Be Litigators' New Normal Even Post-Pandemic
• Talks Underway To End Cocrystal Pharma Stock-Drop Suit
• £220M NHS Suit Over Drug Patent Heads To Supreme Court
• CEO's Junk-Fax Win Can't Help Med Supply Co., 7th Circ. Says
• Takeda, Eli Lilly Lose High Court Bid Over Actos RICO Claims
• 7th Circ. Sanctions Amazon Seller Over Doomed Appeal
• 3 Firms Assist As Brookfield Injects $260M Into Superior Plus
• Teva Invalidates Opiant Patents In Narcan Suit
• Calif. Trial To Decide Risk Of Fluoride In Drinking Water
• 3M Says Ex-Marine Faked Bill Gates Ties In Massive N95 Scam
• Trio Of Life Science Cos. Raise Combined $660M In IPOs
• Coronavirus Q&A: King & Spalding's Health Team Leader
• Crackdown On Chinese Cos. Could Be A Double-Edged Sword
• FCA Ruling Shows Importance Of Relator As Original Source
• The Week In Bankruptcy: Eyes On The New Normal
• Investors Accuse Curaleaf Of Downplaying Stock Drop Claims
• Chinese Investors Urge 9th Circ. To Uphold Discovery Order
• Law Firms Must Beware Risks In Nontraditional Financing
• 'The Government Said I Could' As A Defense During COVID-19
• ED Treatment Maker Nears Deal With Rival In Contract Spat
• Fed. Circ. Won't Say If Premature Alice Ax Bars Invalidity Bid
• COVID-19 IP Catch-Up: Publishers, Vodka Co. Head To Court
• Crucial COVID-19 Drug Patent Considerations For Universities
• Proskauer Assists As Atlas Venture Wraps Up $400M Fund
• Health Hires: Epstein Becker, Clyde & Co., Prevail
• CardioNet Tries To Save Patent By Citing IP Win In Other Case
• 4 Highlights As CDC Chief Eyes Perilous Path For Pandemic
• Conn. Health Care Worker Says She Was Axed For Medical Pot
• Fed. Circ. Says It Can't Award Atty Fees Tied To PTAB Cases
• Drug Firm Hurt By Coronavirus Gets Ch. 11 Plan OK'd
• Invisalign Maker Says Judge Botched Antitrust Analysis
• Iowa Legislators Pass Bill Limiting Medical Marijuana THC
• EU High Court Told To Uphold €94M Pay-For-Delay Fine
• Market Recovery Gains Steam With ZoomInfo's $935M IPO
• Coronavirus Litigation: The Week In Review
• Calif. Pot Regulators Limit Public Licensee Info After Looting
• Inovio Sues Supplier For Holding COVID-19 Vaccine 'Hostage'
• Chancery Advances Investors' $1.2B Drug Control Suit
• Wilson Sonsini-Led Pharma Co. Scores $85M In Funding
• 2 Tested Alternatives To Unavoidable Court Delays
• Minn. Ruling Represents Sensible Stance On Legal Finance
• 2nd Circ. Sends Amazon Customer's Drug Row To Arbitration
• Beware Fraud And Abuse Pitfalls In Precision Medicine
• Ill. High Court Boots Out-Of-Staters From Bayer Device Suit
• UK Pharma Exec Barred After Admitting To Drug Supply Plot
• No Cert. For End-Payors In Niaspan Pay-For-Delay MDL
• 9th Circ. Nixes EPA Approval Of Dicamba Herbicides
• SEC Sues Fla. Firm Pushing Investments In COVID-19 Cure
• Fed. Circ. Judge Probes 'Possible Mischief' In Biosimilar Law
• Opioid MDL Judge Orders More Briefing On $3B Atty Fees
• Gilead Can't Shake New HIV Antitrust Complaint, Court Told
• 2nd Circ. Sends FCA Discount Case For 'Original Source' Look
• Pharmacy Chain Says It Can Rep Class If Lead Is DQ'd
• Portola Investor Cries Foul Over Tender Offer Math
• And Now A Word From The Panel: Pandemic MDLs
• Best Practices For A Paperless Law Practice
• Fed. Circ. OKs Pharma Delivery Co.'s Mixed $24M Breach Win
• Purdue's Ch. 11 Claim Deadline Bumped 30 Days For Virus
• Fla. Judge Recuses Himself In CR Bard Vein Filter Suit
• How Licensing Affects Patent Damages Apportionment: Part 3
• Mylan Gets OK To Sell Generic Insomnia Drug During IP Fight
• Goodwin-Led Pliant Therapeutics Shares Pop After $144M IPO
• Cannabis Lobbies Urge 9th Circ. To Dump Pot Biz Tax Law
• 4 Highlights As Senators Eye FDA Actions On COVID-19
• 1st Circ. Says Novo Nordisk Can't Block Ex-Worker's New Job
• Investors Fight Cannabis Co.'s Bid To Nix Stock-Drop Suit
• Monsanto Says $78M Roundup Verdict Barred By Federal Law
• Amgen Drops Alexion Blood Drug IPRs, Gets 2025 License
• PhRMA Says Fed. Circ. Botched Patent Term Extension Ruling
• Coronavirus Regulations: A State-By-State Week In Review
• 5 Ways A Special IG Can Combat Crisis Relief Fraud
• Sanofi Boots Some Plaintiffs From Chemo Hair Loss MDL
• Lawyers Must Address Racial Injustice With Radical Candor
• How NJ Talc Case May Shift NY Courts On Expert Testimony
• Calif. Dental Board Says SmileDirect Claims Still Not Straight
• Acadia Can't Slip Investor Suit Over Parkinson's Drug Deaths
• ZoomInfo, Pliant Therapeutics Bulk Up IPOs Before Pricing
• Pet Supply Co. Trims $12.6M Award In Product Patent Suit
• Teva Can't Escape Infringement Claim In Inhaler Patent Suit
• Esperion Investor Class Wins Cert. In Cholesterol Drug Row
• Drug Co. Wants 'Free Pass' For Shady Opioid Sales, DOJ Says
• Imprisoned NECC Pharmacist Can't Get COVID-19 Release
• Rhode Island High Court Upholds Medical Pot Patient's Firing
• EPA Finalizes Ethylene Oxide Reduction To Lower Cancer Risk
• Generics' 2nd Challenge To Acne Drug IP Succeeds At PTAB
• Asbestos Battles Show One Possible Fate For J&J After Talc
• Contractors Can't Escape Insurer's $1.4M Water Damage Suit
• Bausch Says Investors' Price-Gouging Claims Came Too Late
• Seed Co. Gets Award For Stolen Trade Secret Upped To $9M
• COVID-19 Securities Catch-Up: SEC Enforcement
• 3 Firms Help Two Biotechs Term IPOs Worth $205M
• How Lawyers Can Network Better, Virtually And In Person
• Practical Tips For Presenting Your Case To Litigation Funders
• Compliance Tips For Development Bank COVID-19 Projects
• Immunomedics Must Face Suit Over Drug Presentation Claims
• Bayer Slams Pet Med Co.'s Bid To Serve Docs Via Email
• Quinn Emanuel Nabs Ex-Williams & Connolly Patent Pro In DC
• Lieff Cabraser Snags $40M Fees From Sandoz, Momenta Deal